Abstract
Corticotropin releasing factor (CRF) receptors belong to the secretin family of G proteincoupled receptors (GPCRs) and are responsible for initiating endocrine stress responses and mediating anxiety related behaviors upon activation via stressors. The main binding site for the CRF ligands is the first extracellular domain (ECD) of the receptors. Several structures of ligand-free and ligand-bound ECDs were recently determined either by nuclear magnetic resonance (NMR) spectroscopy or X-ray crystallography. They reveal how the ligands bind through both hydrophobic and hydrophilic interactions to the ECDs, which is highly dynamic in the absence of ligands. It is the purpose of this review to discuss these structures with a particular focus on ligand-receptor interaction.
Keywords: GPCR, CRF receptors, first extracellular domain, structure, ligand binding, ECD.
Graphical Abstract
Current Molecular Pharmacology
Title:Structures of the First Extracellular Domain of CRF Receptors
Volume: 10
Author(s): Viviane Zelenay, Marilyn Perrin and Roland Riek*
Affiliation:
- Department of Physical Chemistry, ETH Zurich, Vladimir-Prelog-Weg 2, 8093 Zurich,Switzerland
Keywords: GPCR, CRF receptors, first extracellular domain, structure, ligand binding, ECD.
Abstract: Corticotropin releasing factor (CRF) receptors belong to the secretin family of G proteincoupled receptors (GPCRs) and are responsible for initiating endocrine stress responses and mediating anxiety related behaviors upon activation via stressors. The main binding site for the CRF ligands is the first extracellular domain (ECD) of the receptors. Several structures of ligand-free and ligand-bound ECDs were recently determined either by nuclear magnetic resonance (NMR) spectroscopy or X-ray crystallography. They reveal how the ligands bind through both hydrophobic and hydrophilic interactions to the ECDs, which is highly dynamic in the absence of ligands. It is the purpose of this review to discuss these structures with a particular focus on ligand-receptor interaction.
Export Options
About this article
Cite this article as:
Zelenay Viviane, Perrin Marilyn and Riek Roland*, Structures of the First Extracellular Domain of CRF Receptors, Current Molecular Pharmacology 2017; 10 (4) . https://dx.doi.org/10.2174/1874467210666170110120301
DOI https://dx.doi.org/10.2174/1874467210666170110120301 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
CB1 Cannabinoid Receptor Ligands
Mini-Reviews in Medicinal Chemistry β-Lactams as Neuroprotective Agents
Anti-Infective Agents in Medicinal Chemistry Intrathecal Administration of Melatonin Ameliorates the Neuroinflammation- Mediated Sensory and Motor Dysfunction in A Rat Model of Compression Spinal Cord Injury
Current Molecular Pharmacology Pharmacological Prolyl Hydroxylase Domain Inhibition as a Therapeutic Target for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Indole Prenyltransferases from Fungi: A New Enzyme Group with High Potential for the Production of Prenylated Indole Derivatives
Current Medicinal Chemistry Aporphine Alkaloids and their Antioxidant Medical Application: From Antineoplastic Agents to Motor Dysfunction Diseases
Current Organic Chemistry Drug Likeness and Selective Functionalization of Quinoxalines
Current Organic Synthesis In Silico Studies Revealed Multiple Neurological Targets for the Antidepressant Molecule Ursolic Acid
Current Neuropharmacology Cardiovascular Concern of 5-HT2B Receptor and Recent Vistas in the Development of Its Antagonists
Cardiovascular & Hematological Disorders-Drug Targets Butyrylcholinesterase K and Apolipoprotein ε4 Affect Cortical Thickness and Neuropsychiatric Symptoms in Alzheimer’s Disease
Current Alzheimer Research Autophagy: For Better or for Worse, in Good Times or in Bad Times …
Current Molecular Medicine Clinical Herbal Interactions with Conventional Drugs: From Molecules to Maladies
Current Medicinal Chemistry Prolactin Protects Against the Methamphetamine-Induced Cerebral Vascular Toxicity
Current Neurovascular Research NMDA Receptor Antagonists as Antidepressant and Antidementia Drugs: Recent Developments and Future Prospects
Current Medicinal Chemistry - Central Nervous System Agents Neuroprotective Effects of Drug-Induced Therapeutic Hypothermia in Central Nervous System Diseases
Current Drug Targets GABAB Receptors-Associated Proteins: Potential Drug Targets in Neurological Disorders?
Current Drug Targets Adiposity and Alzheimers Disease
Current Alzheimer Research Oxidative Stress and Altered Mitochondrial Function in Neurodegenerative Diseases: Lessons From Mouse Models
CNS & Neurological Disorders - Drug Targets Growth Factor Therapy in Atherosclerotic Disease-Friend or Foe
Current Pharmaceutical Design Nicotinamide Supplementation Protects Gestational Diabetic Rats by Reducing Oxidative Stress and Enhancing Immune Responses
Current Medicinal Chemistry